Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
IFNs are cytokines with important antiproliferative activity and exhibit key roles in immune surveillance against malignancies. Early work initiated over three decades ago led to the discovery of IFN receptor activated Jak–Stat pathways and provided important insights into mechanisms for transcriptional activation of IFN-stimulated genes (ISG) that mediate IFN biologic responses. Since then, additional evidence has established critical roles for other receptor-activated signaling pathways in the induction of IFN activities. These include MAPK pathways, mTOR cascades, and PKC pathways. In addition, specific miRNAs appear to play a significant role in the regulation of IFN signaling responses. This review focuses on the emerging evidence for a model in which IFNs share signaling elements and pathways with growth factors and tumorigenic signals but engage them in a distinctive manner to mediate antiproliferative and antiviral responses. Mol Cancer Res; 12(12); 1691–703. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA biogenesis: coordinated cropping and dicing
Kim, V. N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1644 · Cited by 2,546
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154 · cited 4×
“Although the emergence of new targeted therapies and more effective agents have minimized the use of IFNs in the treatment of diseases like HCL and CML, IFNs are still used extensively in the treatment of melanoma, CTCL and MPNs (1, 16, 17).”
InfluentialMutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923
MicroRNA-155 Modulates Treg and Th17 Cells Differentiation and Th17 Cell Function by Targeting SOCS1
Yao, R., Ma, Y.-L., Liang, W., Li, H.-H., Ma, Z.-J., Yu, X., & Liao, Y.-H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046082 · Cited by 309
Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.017 · Cited by 297
Sadzak, I., Schiff, M., Gattermeier, I., Glinitzer, R., Sauer, I., Saalmüller, A., Yang, E., Schaljo, B., & Kovarik, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801794105 · Cited by 166
Kim, J.-H., Choi, D.-J., Jeong, H.-K., Kim, J., Kim, D. W., Choi, S. Y., Park, S.-M., Suh, Y. H., Jou, I., & Joe, E.-H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.007 · Cited by 102
Rozovski, U., Calin, G. A., Setoyama, T., D’Abundo, L., Harris, D. M., Li, P., Liu, Z., Grgurevic, S., Ferrajoli, A., Faderl, S., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-50 · Cited by 55 · cited 1×
“STAT5 suppresses expression of miR15/16 (116) and there is evidence that there are potential STAT3 binding sites in the promoters of about 200 miRs (117).”
García-Ruiz, I., Solís-Muñoz, P., Gómez-Izquierdo, É., Muñoz-Yagüe, M. T., Valverde, Á. M., & Solís-Herruzo, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342709 · Cited by 22
Cited by
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
“As the interferon gamma receptor pathway downstream of JAK1/2 controls the expression of chemokines with potent chemoattractant effect on T cells, such as CXCL9, CXCL10 and CXCL11 (28), it is possible that an important effect of JAK1/2 loss may result in lack of T cell infiltrates.”
BackgroundInterferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423
Ren, D., Hua, Y., Yu, B., Ye, X., He, Z., Li, C., Wang, J., Mo, Y., Wei, X., Chen, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1144-6 · Cited by 316
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Metadata
- Authors
- Fish, E. N., & Platanias, L. C.
- Venue
- Molecular Cancer Research
- Published
- 2014-12-17
- Volume
- 12
- Issue
- 12
- Pages
- 1691-1703
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2328043056
- Cited by
- 87
- References
- 9
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-14-0450
- The paper
- Fish, E. N., & Platanias, L. C. (2014). Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-14-0450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.